Clinical Outcome of CT-guided Radioactive Iodine-125 Seeds Implantation for Inoperable Early Stage Non-small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 39
- 主要终点
- Local control time
研究概览
简要总结
This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.
详细描述
Radioactive Iodine-125 seed brachytherapy is a conventional treatment in Peking University Third Hospital. Radioactive Iodine-125 seed brachytherapy is the implantation of Iodine-125 seed into tumors.The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. This study collects the data of patients with early stage (stage I-II, N0) non-small cell lung cancer who underwent CT-guided radioactive Iodine-125 seed implantation from 2010 to 2018. The investigators evaluate the dose that covers 90% target volume(D90) and other parameters after the implantation. The efficacy and adverse effects were observed. Local control(LC) time and overall survival(OS) time are evaluated.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histological proven non-small cell lung cancer
- •UICC (Union for International Cancer Control) stage was T1-3N0M0 (stage Ia-IIb)
- •inoperable and CT-guided radioactive iodine-125 seeds brachytherapy was used as the initial treatment without external beam radiotherapy
排除标准
- •actual dose of covers 90% target volume (D90) less than 100 Gy in postoperative validation
- •case information and/or follow-up information was unavailable
结局指标
主要结局
Local control time
时间窗: Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.
The time from the date of seeds implantation to the date of recurrence of the implanted tumor or the date of last observation.
Overall survival time
时间窗: Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.
The time from the date of seeds implantation to the date of death from any cause or the date of last observation.
次要结局
- Incidence of adverse events(Outcomes were followed up every 3 months after seeds implantation. The last follow-up timepoint is February 2019.)